Adacel Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established tdap vaccination schedules, recurring pertussis outbreaks, public health immunization policies, clinical efficacy of booster vaccines, school and workplace vaccination mandates.

The growth in the forecast period can be attributed to growing adult immunization coverage, expansion of booster dose recommendations, rising healthcare awareness, government supported vaccination drives, improved vaccine access channels. Major trends in the forecast period include sustained demand for adolescent and adult booster vaccines, rising focus on pertussis prevention, expansion of public immunization programs, improved awareness of lifelong vaccination needs, increased use in preventive healthcare strategies.

The increase in children’s vaccination is expected to drive the growth of the adacel market in the coming years. Children’s vaccination involves administering vaccines to children to protect them from a range of infectious diseases. The growth in childhood vaccination is supported by greater public awareness, improved access to healthcare services, government-led immunization programs, and advances in vaccine development, all of which aim to prevent childhood illnesses and strengthen public health outcomes. Adacel supports children’s vaccination by offering protection against three serious diseases - diphtheria, tetanus, and pertussis (whooping cough) - through a single injection, thereby lowering the risk of these infections among young children. For instance, in July 2024, the Pan American Health Organization, a US-based health agency, reported that global childhood immunization coverage stagnated in 2023, resulting in 2.7 million more children being under-vaccinated compared with pre-pandemic levels. Therefore, the rise in children’s vaccination is contributing to the growth of the adacel market.

Major companies operating in the adacel market are focusing on expanding age indications to extend the vaccine’s use across broader age groups, enhancing public health protection and increasing market penetration. Adacel supports expanded age populations by delivering essential protection against tetanus, diphtheria, and pertussis, which pose greater risks in older adults due to waning immunity, higher susceptibility to complications, and the potential for severe disease outcomes, thereby serving as a booster to maintain immunity and reduce infection risk in this vulnerable population. For instance, in January 2023, Sanofi Pasteur Limited, a France-based biopharmaceutical company, received approval from the Food and Drug Administration in the United States for the use of Adacel during the third trimester of pregnancy. This approval is intended to help protect infants younger than two months from pertussis. This approach improves vaccine effectiveness, broadens accessibility, and enhances patient safety, thereby supporting global public health initiatives aimed at preventing infectious diseases. Adacel is a Tdap vaccine developed for active booster immunization against tetanus, diphtheria, and pertussis, primarily for individuals aged 10 to 64 years.

In March 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, entered into a partnership with Sanofi Healthcare India Private Limited. This collaboration is designed to expand access to Adacel across India, ensuring its availability in both urban and rural healthcare settings. Such efforts are critical to meeting the need for widespread immunization to prevent pertussis outbreaks, particularly among vulnerable groups such as infants and pregnant women. Sanofi Healthcare India Private Limited is an India-based biopharmaceutical company focused on the development of vaccines, including adacel.

Major companies operating in the adacel market are Sanofi Pasteur.

North America was the largest region in the adacel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adacel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adacel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the adacel market by increasing costs associated with vaccine antigen sourcing and sterile manufacturing inputs. These impacts are most evident in public health procurement and pharmacy distribution channels. Higher tariffs have added pressure on vaccination program budgets. At the same time, tariffs are supporting domestic vaccine manufacturing expansion. This strengthens long term supply resilience for booster immunizations.

The adacel market research report is one of a series of new reports that provides adacel market statistics, including adacel industry global market size, regional shares, competitors with a adacel market share, detailed adacel market segments, market trends and opportunities, and any further data you may need to thrive in the adacel industry. This adacel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adacel is a vaccine that provides protection against tetanus, diphtheria, and pertussis (whooping cough). It is commonly administered as a booster dose for individuals aged 10 years and older. Adacel stimulates the immune system to produce antibodies against tetanus, diphtheria, and pertussis toxins without causing the diseases themselves, using inactivated toxins (toxoids) and purified antigens to induce long-lasting immunity.

The main vaccine types in the adacel market include Tdap vaccines and combination vaccines. Tdap vaccines are combination formulations that protect against tetanus, diphtheria, and pertussis. Clinical indications include pertussis (whooping cough), diphtheria, and tetanus, across age groups such as pediatric, adult, and geriatric populations. Distribution channels include direct tenders, pharmacies, and online pharmacies, with end users comprising hospitals, clinics, and public health programs.

The adacel market consists of sales of single-dose prefilled syringes and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.